Cagrilintide + Semaglutide Peptide For Sale

Buy Cagrilintide + Semaglutide peptide: 10mg listed purchase quantities. Compare live prices across 2 listed vendors with real cost per mg, recorded COA availability and discount codes.

Buy Cagrilintide + Semaglutide peptide starting at $84.15/purchase from 2 listed vendors. Compare 10mg purchase quantity options by cost per mg, price per purchase, monthly cost, discount codes and recorded COA metadata (not independent verification).

About Cagrilintide + Semaglutide

In clinical trialsAlso known as: CagriSema · AM833 + semaglutide

Cagrilintide + Semaglutide (CagriSema) is a research-grade blend of an amylin analog (cagrilintide) and a GLP-1 agonist (semaglutide), most often sourced for weight-management and metabolic research. Novo Nordisk's pharmaceutical version completed Phase 3 obesity trials but is not yet FDA-approved. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1][2]

What to check before you buy Cagrilintide + Semaglutide:

  • A third-party COA that confirms BOTH peptides by mass spec — cagrilintide and semaglutide — at ≥98% purity by HPLC, since a blend can ship off-ratio or missing one component.
  • A COA dated within the last 6–12 months that matches the exact vial size, batch, and stated mg-per-peptide ratio you are buying.
  • Accurate vial fill for each peptide: off-ratio or under-filled blend vials are a common failure mode and throw off every reconstitution and dosing calculation.

REDEFINE-1 reported mean weight loss of approximately 22.7% at 68 weeks on the highest-dose CagriSema arm versus 16.1% on semaglutide alone and 11.8% on cagrilintide alone, in adults with obesity but without T2D — confirming meaningful additive benefit over either component, though the headline figure undershot Novo's pre-trial expectation of ~25%.[1] REDEFINE-2 reported approximately 13.7% mean weight loss at 68 weeks in adults with obesity and T2D, with A1C reductions in the 1.8–2.0% range.[2] A Phase 2 study (Frias et al., Lancet 2021) established the dose-response profile.[3] See also the standalone Cagrilintide and Semaglutide entries for component-level detail.

Regulatory: Not FDA- or EMA-approved. REDEFINE-1 and REDEFINE-2 Phase 3 obesity trials read out 2024–2025; regulatory filings in preparation. Research-grade material elsewhere.

Read the full mechanism & research breakdown

Cagrilintide + Semaglutide: Mechanisms, Half-Life & Research Data

A skimmable deep dive into how Cagrilintide + Semaglutide works and what it is being studied for — tied back to what size to buy. Detailed debates and community notes are tucked into the expandable panels below. All citations resolve to the sources list at the bottom of this page.

How it works

CagriSema is a fixed-ratio combination of two distinct molecules — cagrilintide and semaglutide — co-administered as a single once-weekly subcutaneous injection. The pharmacology of each component is detailed in their standalone entries; the combination rationale rests on activating two complementary appetite-regulating pathways. The semaglutide arm binds the GLP-1 receptor, producing the now-familiar GLP-1 effects: slowed gastric emptying, glucose-dependent insulin release, glucagon suppression, and hypothalamic appetite suppression through arcuate-nucleus POMC and AgRP circuits. The cagrilintide arm activates amylin receptors (heterodimers of the calcitonin receptor with receptor activity-modifying proteins, RAMP1/2/3) primarily in the area postrema and adjacent brainstem nuclei, producing satiety signalling through a pathway that is largely non-overlapping with GLP-1.[7] Both components carry fatty-acid sidechains that bind albumin and extend each half-life to roughly one week — letting them be co-formulated and dosed weekly. The clinical hypothesis is that activating two non-overlapping pathways will produce additive or supra-additive weight loss compared with either component alone, while permitting lower doses of each to minimise side effects.

Active research areas

  • Obesity without T2D (REDEFINE-1, December 2024 readout)
    REDEFINE-1 reported mean weight loss of approximately 22.7% at 68 weeks on the highest-dose CagriSema arm versus 16.1% on semaglutide 2.4mg alone and 11.8% on cagrilintide alone, in adults with obesity but without T2D — confirming additive benefit beyond either component. The headline figure undershot Novo's pre-trial guidance of ~25%, partly because the trial permitted dose flexibility (more than half of participants on the CagriSema arm were not at the highest dose at week 68) which the company has emphasised in interpretation.[1][4]
  • Obesity with T2D (REDEFINE-2, March 2025 readout)
    REDEFINE-2 reported mean weight loss of approximately 13.7% at 68 weeks in adults with obesity and T2D — meaningfully larger than what semaglutide alone produces in the same population, and accompanied by A1C reductions in the 1.8–2.0% range.[2][5]
  • Cardiovascular outcomes (REDEFINE-CV, planned)
    Novo has signalled a cardiovascular-outcomes trial to support the post-approval label, building on the SELECT semaglutide cardiovascular benefit. The trial would test whether the additional weight loss from adding cagrilintide produces additional cardiovascular event reduction beyond what semaglutide alone delivers.
  • Phase 2 dose-finding (Lau 2021)
    The Phase 2 dose-finding trial of cagrilintide alone established the dose-response curve, with the 4.5mg weekly dose producing approximately 10.8% weight loss at 26 weeks as monotherapy — supporting the use of cagrilintide as the partner agent in CagriSema rather than as a standalone obesity therapy.[6]
  • MASH and other metabolic indications
    Active early-phase work explores CagriSema in metabolic dysfunction-associated steatohepatitis and other GLP-1-class adjacent indications, leveraging the established GLP-1 effect on hepatic fat and the amylin contribution to body-composition changes.
Open questions & leading hypotheses (2)
  • Hypothesis: The amylin–GLP-1 combination is genuinely additive on weight loss — adding cagrilintide to semaglutide produces meaningfully more weight loss than maximising the semaglutide dose alone.
    Evidence: REDEFINE-1 reported 22.7% weight loss on CagriSema versus 16.1% on semaglutide 2.4mg alone — roughly 7 percentage points of additional weight loss attributable to the cagrilintide arm.[1] Counter-evidence: the headline result undershot the pre-specified 25% expectation; tirzepatide (SURMOUNT-1) produced approximately 20.9% weight loss on monotherapy, narrowing the practical gap between the two-component CagriSema regimen and tirzepatide. The economic and adherence case for adding a second component may be smaller than the trial result implies once tirzepatide and retatrutide are factored in.
  • Hypothesis: CagriSema's side-effect profile is meaningfully better than dose-titrating semaglutide to its highest doses to chase additional weight loss.
    Evidence: The Phase 1b dose-finding work and the REDEFINE program reported gastrointestinal tolerability broadly comparable to semaglutide alone, with the amylin component not adding a substantial new tolerability concern.[3] Counter-evidence: amylin agonism has its own side-effect profile (nausea, injection-site reactions historically prominent with pramlintide); long-term tolerability of dual mechanism activation in real-world settings has not been characterised beyond the trial population.
What community users report

Anecdotal — not controlled-trial evidence

CagriSema community discussion is limited because the molecule is not yet approved or commercially available; most threads on r/Semaglutide and r/PeptideAdmin focus on the published REDEFINE-1 results and speculation about pricing, availability, and how it will compare to tirzepatide and retatrutide once approved.[8] A small cohort of users self-experimenting by co-injecting research-grade cagrilintide alongside their existing semaglutide therapy report subjective effects consistent with the trial data (modestly stronger appetite suppression than semaglutide alone, similar GI profile), but the practice of unsupervised combination dosing introduces meaningful safety risks not present in the supervised trial. **These reports are anecdotal, are based on small numbers of users running unapproved combinations outside any clinical trial, and have not been validated in controlled trials.** CagriSema is not approved for use outside ongoing clinical trials in any jurisdiction.

Sources & references (8)

Peer-reviewed literature, FDA documents, and trial registrations cited above. Vendor pricing, COA data, and live calculator statistics shown elsewhere on this page are sourced from the WPA database independently of this list.

  1. [1]Novo Nordisk press release — REDEFINE-1 Phase 3 results for CagriSema in adults with obesity, December 20, 2024. link
  2. [2]Novo Nordisk press release — REDEFINE-2 Phase 3 results for CagriSema in adults with obesity and type 2 diabetes, March 2025. link
  3. [3]Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, Phase 1b trial. Lancet 2021;397:1736–1748. · PMID: 33894838 link
  4. [4]ClinicalTrials.gov: REDEFINE-1 (NCT05567796) — Phase 3 CagriSema in adults with obesity. link
  5. [5]ClinicalTrials.gov: REDEFINE-2 (NCT05394519) — Phase 3 CagriSema in adults with obesity and type 2 diabetes. link
  6. [6]Lau DCW et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 2021;398:2160–2172. · PMID: 34798060 link
  7. [7]Hay DL et al. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 2015;67:564–600. · PMID: 26071095 link
  8. [8]Community report — r/Semaglutide and r/PeptideAdmin CagriSema discussion threads (subreddits), accessed May 2026. link

What Cagrilintide + Semaglutide Costs Right Now

WPA currently tracks Cagrilintide + Semaglutide from 2 distinct vendors. The cheapest in-stock Cagrilintide + Semaglutide listing is $84.15. Glow Aminos holds the lowest sticker price at $84.15. Normalized to milligrams, Cagrilintide + Semaglutide costs $8.42/mg on this page. The best per-milligram value is the listed 10 mg purchase quantity from Glow Aminos.

Cagrilintide + Semaglutide is stocked in a single size: 10 mg listed quantity; vial count not recorded. Because vials of different strengths rarely scale linearly in price, the per-milligram column is the only fair way to rank them.

Ranked by true cost per milligram, the Cagrilintide + Semaglutide listings WPA tracks are: Glow Aminos — 10mg at $84.15 ($8.42/mg), COA purity 99.85%; Flawless Compounds — 10mg at $84.15 ($8.42/mg), COA purity 99.85%.

Cagrilintide + Semaglutide COA Coverage Across Tracked Vendors

2 of the 2 tracked Cagrilintide + Semaglutide listings (100%) are marked as having COA availability in WPA's listing data; this marker is not independent verification. A purity value is recorded for 2 listings; purity alone does not establish identity or independent testing. The recorded purity values range from 99.85% to 99.85%. 2 listings record more Cagrilintide + Semaglutide in the vial than the label claims; check the vendor's report and batch before drawing conclusions. The latest COA date recorded in WPA's listing data is 3/26.

To assess a COA, inspect the actual report for the independent lab, test date, and a batch and vial size matching the Cagrilintide + Semaglutide offer. WPA's listing fields do not establish that a report was independently verified.

Cagrilintide + Semaglutide Calculator Input Observations

In lifetime Cagrilintide + Semaglutide calculator inputs, 2mg is the most frequent entered amount (6 of 48 runs). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. As nominal quantity arithmetic only, 10 mg of listed product divided by 2 mg gives roughly 5.0 portions before preparation losses. This does not establish vial count, stability after preparation, or cycle length.

Cagrilintide + Semaglutide Discount Codes

2 of the 2 tracked Cagrilintide + Semaglutide listings carry a WPA researcher discount code. The largest live discount is 15% off. Every price and per-milligram figure on this page is the post-discount number, so you are never comparing a discounted listing against an undiscounted one. Codes change and some exclude sale items or carry order minimums.

About Cagrilintide + Semaglutide

Cagrilintide + Semaglutide (CagriSema) is a research-grade blend of an amylin analog (cagrilintide) and a GLP-1 agonist (semaglutide), most often sourced for weight-management and metabolic research. Novo Nordisk's pharmaceutical version completed Phase 3 obesity trials but is not yet FDA-approved. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.

Cagrilintide + Semaglutide is tracked under the Weight Loss category on WPA. Its reported half-life is ~7 days (both components). Calculator inputs do not establish why a cadence was selected or validate a protocol. Not FDA- or EMA-approved.

How to Read the Cagrilintide + Semaglutide Comparison

  • Price per milligram — Every Cagrilintide + Semaglutide listing is normalized to $8.42/mg-style unit pricing, so a small cheap vial cannot hide a worse real cost than a larger one.
  • COA metadata and purity — 2 Cagrilintide + Semaglutide listings are marked for COA availability, and 2 have a recorded purity value. These fields do not independently verify a report.
  • Stock status — Live in-stock state for each Cagrilintide + Semaglutide listing, refreshed on a recurring basis.

Frequently Asked Questions: Cagrilintide + Semaglutide

Is it legal and safe to buy Cagrilintide + Semaglutide for research?

In the US, Cagrilintide + Semaglutide is sold strictly as a research chemical — legal to buy for laboratory research but not approved for human use. Both peptides are sold strictly as research chemicals with no approved human form for the blend, intended for laboratory use only. The real variable isn't legality, it's quality: unverified suppliers can ship underdosed, impure, or mislabeled material. WPA records COA-related listing fields where supplied, but does not independently verify every report. Inspect the actual batch report and its laboratory, identity testing, and date before drawing conclusions. Right now that screen covers 2 Cagrilintide + Semaglutide listings from 2 vendors.

How do I verify a Cagrilintide + Semaglutide COA so I'm not getting an underdosed vial?

A Certificate of Analysis (COA) may report tests for a specific Cagrilintide + Semaglutide batch. Check that the report identifies the compound (both cagrilintide and semaglutide at the labeled ratio, not just one of the two or an underdosed mix), names the laboratory, describes the test method and result, and matches the offered batch and date. A recorded purity value or COA-availability flag in WPA's listing data is not independent verification. Open the vendor listing and inspect the actual report before drawing conclusions. For Cagrilintide + Semaglutide specifically, 2 of 2 tracked listings (100%) are marked as having COA availability in WPA's listing data; that marker is not independent verification. A purity value is separately recorded for 2 listings; purity alone does not establish identity or independent testing. The latest COA date recorded in the listing data is 3/26.

Which Cagrilintide + Semaglutide vendor should I pick?

There's no single "best" Cagrilintide + Semaglutide vendor — it depends on what you weigh most. WPA ranks tracked listings using recorded purity and date fields where available, visitor click activity, price, stock status, and discount data; this ranking is not independent verification of a report. For a blend, COA identity matters double — a good vendor's COA confirms both peptides are present at the stated amounts, and ratios drift if formulation isn't tightly controlled. 2 vendors currently carry Cagrilintide + Semaglutide, and Glow Aminos holds the best true value at $8.42/mg on the 10 mg listed purchase quantity. Review the actual report and confirm its batch details before making a decision.

How much does Cagrilintide + Semaglutide cost — and how do I know I'm not overpaying?

Judge Cagrilintide + Semaglutide by true price per milligram, not the sticker price on one vial — a cheap small vial often costs more per mg than a larger one. It is usually sold as a single combined vial, and buying the two peptides pre-blended is normally cheaper than sourcing them separately. The best tracked Cagrilintide + Semaglutide listing works out to $8.42/mg on the listed 10 mg purchase quantity. WPA normalizes tracked listings to $/mg, and the live cost-per-month card estimates your spend at the most common dose. The one catch: the lowest $/mg sometimes means buying a bigger vial than your cycle needs.

How much Cagrilintide + Semaglutide do I need for one full cycle?

In lifetime Cagrilintide + Semaglutide calculator inputs, 2mg is the most frequent entered amount (6 of 48 runs). Calculator runs and frequency responses are different populations, not unique people or confirmed administration. Separate modal inputs do not establish a most-common joint protocol, a recommendation, or a cycle length. Dividing the listed 10 mg purchase quantity by 2 mg gives roughly 5.0 nominal portions before preparation losses; vial count and stability after preparation are separate questions. A cycle requires an independently chosen amount, cadence and time horizon; calculator observations do not supply those decisions. Compare nominal package quantities and model your own selections in the cost card.

Are discount codes available for Cagrilintide + Semaglutide?

Participating Cagrilintide + Semaglutide vendors may offer WPA researcher discount codes. Codes can change, exclude sale items or carry order minimums. 2 of the 2 tracked Cagrilintide + Semaglutide listings carry a code right now, the largest worth 15% off. Each listing shows the recorded code and discounted price where available; confirm the actual package and checkout terms with the vendor.

Where can I compare Cagrilintide + Semaglutide prices and listing details?

This comparison shows 2 tracked listings for Cagrilintide + Semaglutide in the selected format. Compare purchase price, established nominal quantities, discount terms and recorded COA availability, purity and date fields. Those fields are not independent verification. Inspect actual batch reports and confirm package composition and checkout price on the vendor's site.